Treatments

*April 2022* Lung cancer remains the leading cause of cancer-related deaths in the U.S. Lung cancer in non-smokers is more common than many people realize. In fact, lung cancer in never-smokers is now considered the 6th most common cause of cancer deaths in the United States. Each year lung cancer…

*April 2022* Note: Current guidelines state that molecular testing should be conducted at the time of initial diagnosis as well as tumor progression on targeted therapies. Meghan J. Mooradian, MD: I think an important question that many clinicians are faced with now is whether to use blood-based assays, tissue-based assays,…

*June 2021* Note: Most research in resistance has been studied in isolation, not accounting for the complexity tumor heterogeneity and the patient heterogeneity. This model was presented at one of the plenary sessions, considers the complex pharmacokinetics and variability of drug concentration in patients, specifically the change in concentrations of multiple…

*April 2022* Drug-tolerant “dormant” cells (DTC) have emerged as one of the major non-genetic mechanisms driving resistance to targeted therapy in lung cancer, although the sequence of events leading to entry and exit from dormancy remain poorly described. Here, we performed real-time monitoring of the cell cycle dynamics during the…

*March 2022* Jill Feldman, EGFR Resisters co-founder, participated in one of the FDA’s Conversations on Cancer public panel discussions, “More Isn't Always Better- Understanding Cancer Treatment Tolerability.” Watch video here.

Cancer that has spread from a solid tumor to the membranes lining the brain and spinal cord (leptomeninges) is called “leptomeningeal metastasis.” Cerebrospinal fluid (CSF) is located between the leptomeninges, in a place called the “intrathecal space.” Cancer cells within the CSF rely on iron for growth and survival. Researchers…

*March 2022* Note: Those who progress on osimertinib and/or chemo with no actionable mutations are candidates for this treatment since HER3 overexpression is found in many EGFR+ lung cancer tumors. Disease progression and acquired resistance to approved EGFR tyrosine kinase inhibitors (TKIs) have resulted in a treatment void in the third- and…

*March 2022* Note: In this article,  Julien Mazieres, MD, PhD, talks R2D2, while Bob Li, MD, PhD, MPH, highlights DESTINY-Lung01 Also note: In the Destiny trial, Drug-related interstitial lung disease (ILD) and pneumonitis remain an important, identifiable risk. The R2D2 trial achieved a first by showing that HER2 mutations can be "treatable targets" in…

*March 2022* PURPOSE Patients with EGFR-mutant non-small cell lung cancer (NSCLC) experience variable duration of benefit on EGFR tyrosine kinase inhibitors (TKI). The effect of concurrent genomic alterations on outcome has been incompletely described. MATERIAL AND METHODS In this retrospective study, targeted next-generation sequencing data was collected from patients with EGFR-mutant lung…

*March 2022* Highlights: The EGFR-TKI efficacy of uncommon EGFR mutations generally considered TKI-sensitive was validated. Complex EGFR mutations containing exon19del or L858R mutations were EGFR TKI sensitive, independent of the combination partner. Very rare single and complex mutations, comprising 40% of atypical mutations, show a high heterogeneity of TKI sensitivity. TP53 co-mutations may confer…